The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 22, 2022

Filed:

Dec. 01, 2016
Applicant:

Stsciences, Inc., Seoul, KR;

Inventors:

Stephen Sunghan Yoo, Centreville, VA (US);

Ezra Myung Chul Chung, North Potomac, MD (US);

Yong-Soo Kim, Rockville, MD (US);

Andrew H. Park, Gaithersburg, MD (US);

Assignee:

STSCIENCES, INC., Seoul, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39558 (2013.01); C07K 16/2818 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); A61P 35/00 (2018.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01);
Abstract

Provided herein are molecules, such as antibodies, that selectively bind to glycosylated BTLA (B- and T-lymphocyte attenuator) relative to unglycosylated BTLA. Methods for making and using such molecules are also provided, including methods for treating or diagnosing cancer. In some embodiments, the anti-glycosylated BTLA antibodies provided herein can immunospecifically bind to glycosylated wild-type BTLA (WT). In some embodiments, the anti-glycosylated BTLA antibodies provided herein can immunospecifically bind to one or more BTLA double mutants that retain only a single glycosylation site at BTLA N75, N94 or N110. In some embodiments, the anti-glycosylated BTLA antibodies provided herein show only background binding, if any, to a BTLA triple mutant, that retains none of BTLA's N75, N94, or N110 0-glycosylation sites.


Find Patent Forward Citations

Loading…